Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/tessa-therapeutics-dissolves-after-raising-more-200m
https://www.globenewswire.com/news-release/2023/06/16/2689643/0/en/Tessa-Therapeutics-Announces-Positive-Results-from-CD30-CAR-T-Combination-Study-with-Nivolumab-in-2nd-line-Hodgkin-Lymphoma.html
https://www.globenewswire.com/news-release/2023/06/16/2689488/0/en/Tessa-Therapeutics-Off-the-Shelf-CAR-T-Therapy-Shows-Promising-Results-in-Early-Stage-Study-of-Hodgkin-Lymphoma.html
https://www.globenewswire.com/news-release/2023/05/30/2678126/0/en/Tessa-Therapeutics-Autologous-and-Allogeneic-Cell-Therapy-Data-to-be-Featured-at-the-17th-International-Conference-on-Malignant-Lymphoma-Lugano.html
https://www.globenewswire.com/news-release/2023/03/08/2622756/0/en/Tessa-Therapeutics-Enters-into-Cooperative-Research-and-Development-Agreement-CRADA-with-the-U-S-National-Cancer-Institute.html
https://www.contractpharma.com/contents/view_breaking-news/2023-03-08/tessa-therapeutics-enters-crada-with-the-national-cancer-institute/?widget=listSection
https://www.fiercebiotech.com/biotech/tessa-plucks-new-years-resolutions-shelf-leaving-phase-2-autologous-med-2022
https://www.globenewswire.com/news-release/2023/01/03/2581907/0/en/Tessa-Therapeutics-Provides-Strategic-Outlook-and-Corporate-Update-for-2023.html
https://www.globenewswire.com//news-release/2022/12/12/2572312/0/en/Tessa-Therapeutics-Announces-Updated-Safety-Efficacy-and-Biomarker-Data-from-Phase-2-Trial-of-Autologous-CD30-CAR-T-Therapy-TT11-in-Relapsed-or-Refractory-Classical-Hodgkin-Lymphom.html
https://www.globenewswire.com/news-release/2022/12/10/2571406/0/en/Tessa-Therapeutics-Announces-New-Clinical-Data-from-Phase-1-Allogeneic-Study-Presented-at-2022-Annual-Meeting-of-American-Society-of-Hematology-ASH.html